Patent application number | Description | Published |
20100272636 | Anti-CD74 Immunoconjugates and Methods of Use - Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing apoptosis of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates or compositions. | 10-28-2010 |
20110027798 | Hybridization Quantitation Method for Modified Micro-RNA and -DNA Based Oligonucleotides - Described herein is a method for the qualitative and/or quantitative determination of an analyte in a test sample which includes base pairing at least one oligonucleotide to a capture template having an overhang; and, hybridizing with a detection probe. | 02-03-2011 |
20110280913 | Methods and Compositions for Delivering Therapeutic Agents in the Treatment of B-Cell Related Disorders - Methods and compositions for treating and/or diagnosing a B-cell malignancy are described. | 11-17-2011 |
20120100068 | Anti-CD74 Immunoconjugates and Methods of Use - Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing apoptosis of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates or compositions. | 04-26-2012 |
20120136063 | FTY720-DERIVED ANTICANCER AGENTS - A number of FTY720-derived compounds with antitumor activity are described. These compounds include the compounds of formula I: | 05-31-2012 |
20130142729 | Anti-CD74 Immunoconjugates and Methods of Use - Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing apoptosis of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates or compositions. | 06-06-2013 |
20140005250 | Compositions and Methods for Increasing Drug Efficacy in Cancer | 01-02-2014 |
20140134265 | TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY - Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections. | 05-15-2014 |
20140371241 | TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY - Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections. | 12-18-2014 |